The use of STS in patients with AS and ASCVD appears to have significantly decreased the levels of pro-inflammatory cytokines IL-6, TNF-α, and IL-1β, adhesion molecules ICAM-1 and p-selectin, and chemokines fractalkine and MCP-1. The gene discussed is CX3CL1; the disease is atherosclerosis.